LifeScience Cell & Gene
Nanoscope Therapeutics, a pioneering biotechnology firm, unveiled groundbreaking results from the Phase 2b RESTORE trial of MCO-010...
March 27, 2024 | News
Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has par...
March 26, 2024 | News
NeuExcell Therapeutics, a leading biotechnology company focused on in vivo neural regenerative therapies, announces the successful dosing of the ...
March 22, 2024 | News
Bristol Myers Squibb announced a significant advancement in the treatment of multiple myeloma with the European Commission's approval of Abecma® (ideca...
March 21, 2024 | News
Metachromatic leukodystrophy is a debilitating, rare genetic disease affecting the brain and nervous system. It is caused by a deficiency of an enzyme call...
March 19, 2024 | News
Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients wit...
March 15, 2024 | News
The Centre for Artificial Intelligence and Robotics (CAIR), under the Hong Kong Institute of Science & Innovation, Chinese Acad...
March 12, 2024 | News
ACROBiosystems, one of the leading providers of innovative tools and solutions used from discovery to the clinic, has announced a new corporate initiative ...
March 05, 2024 | News
CARsgen Therapeutics, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that t...
March 04, 2024 | News
Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been sele...
February 29, 2024 | News
EpCAM, known for its presence in circulating tumor cells (CTCs) and high expression in primary and metastatic lesions of gastrointestinal tumors, r...
February 26, 2024 | News
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Dr...
February 21, 2024 | News
Neurophth Therapeutics, Inc. ("Neurophth"), a pioneer in gene therapies, today announced the successful completion of patient enrollment for its Phase I/II...
February 20, 2024 | News
AMTAGVI marks the first individualized Tumor Infiltrating Lymphocyte (TIL) therapy to receive FDA approval for any cancer. In this innovative thera...
February 17, 2024 | News
Most Read
Bio Jobs
News